Immunogenicity and Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds.

Trial Profile

Immunogenicity and Safety Study of GSK Biologicals' 208136 Vaccine Formulated With New Measles and Rubella Working Seeds.

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Oct 2017

At a glance

  • Drugs MMR-varicella zoster virus vaccine (Primary)
  • Indications Measles; Mumps; Rubella; Varicella zoster virus infections
  • Focus Pharmacodynamics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 23 Dec 2010 Actual end date changed from Mar 2010 to Dec 2010 as reported by ClinicalTrials.gov.
    • 23 Dec 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 16 Jul 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top